^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
01/18/2019
Excerpt:
Ontruzant is a HER2/neu receptor antagonist indicated for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma...Ontruzant is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease.
Secondary therapy:
cisplatin + 5-fluorouracil; cisplatin + capecitabine
Evidence Level:
Sensitive: A1 - Approval
Published date:
11/15/2017
Excerpt:
Ontruzant should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result.